

cancer cell lines, only a minimal or even an undetectable level of Syk expression has been demonstrated in invasive breast carcinoma tissues and cell lines (Coopman *et al.*, 2000). DNA methylation of the CpG sites in the *syk* gene promoter has been reported to be responsible for the loss or marked reduction of Syk expression in breast cancer (Yuan *et al.*, 2001). Moreover, Yuan *et al.* (2006) reported that DNA methylation of the *syk* gene in hepatitis B virus-associated HCC cancerous tissue was highly correlated with Syk expression and that the patients with a methylated *syk* gene had a significantly lower overall survival rate after hepatectomy than those with an unmethylated *syk* gene. In contrast, our results revealed that the expression levels of Syk did not differ between normal and HCV-infected hepatocytes (Fig. 1k) or between cancerous and non-cancerous hepatocytes (data not shown). At the functional level, however, NS5A downregulated Syk kinase activity in Huh-7 cells (Fig. 6). Moreover, Syk kinase activity was downregulated in cells harbouring an HCV RNA replicon (Fig. 7c). These results collectively suggest that NS5A is involved, at least partly, in the suppression of Syk kinase activity in HCV-infected cells. It is also interesting to assume that the NS5A-mediated Syk inhibition plays an important role in the development of HCC, although the precise molecular mechanism(s) is yet to be determined. Recently, a possible mechanism by which breast cancer cells become invasive was proposed: human breast cancer cells express and secrete a group of chemokines called growth-related oncogene (GRO)- α , GRO- β and GRO- γ , and their production is regulated by Syk (Li & Sidell, 2005). It would be interesting to examine the possible effects of NS5A and HCV RNA replication on the levels of GRO expression and secretion.

ACKNOWLEDGEMENTS

The authors are grateful to Dr R. Bartenschlager (University of Heidelberg, Germany) for providing the HCV RNA replicon and Dr C. M. Rice (The Rockefeller University, USA) for pFL-J6/JFH1 and Huh-7.5 cells. Thanks are also due to Dr I. Fuke (Osaka University, Japan) for providing monoclonal antibodies against NS3, NS4A and NS5A, and Dr K. Shimotohno (Institute for Virus Research, Kyoto University, Japan) for anti-NS5A polyclonal antibody. This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Health, Labour and Welfare, Japan. This study was also carried out as part of the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, MEXT Japan, and the 21st Century COE Program at Kobe University Graduate School of Medicine.

REFERENCES

- Blight, K. J., McKeating, J. A. & Rice, C. M. (2002). Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J Virol* 76, 13001–13014.
- Cheng, A. M., Rowley, B., Pao, W., Hayday, A., Bolen, J. B. & Pawson, T. (1995). Syk tyrosine kinase required for mouse viability and B-cell development. *Nature* 378, 303–306.
- Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244, 359–362.
- Chung, K. M., Lee, J., Kim, J. E., Song, O. K., Cho, S., Lim, J., Seedorf, M., Hahm, B. & Jang, S. K. (2000). Nonstructural protein 5A of hepatitis C virus inhibits the function of karyopherin β 3. *J Virol* 74, 5233–5241.
- Coopman, P. J., Do, M. T., Barth, M., Bowden, E. T., Hayes, A. J., Basyuk, E., Blancato, J. K., Vezza, P. R., McLeskey, S. W. & other authors (2000). The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. *Nature* 406, 742–747.
- Corey, S. J., Burkhardt, A. L., Bolen, J. B., Geahlen, R. L., Tkatch, L. S. & Tweardy, D. J. (1994). Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. *Proc Natl Acad Sci U S A* 91, 4683–4687.
- Costello, P. S., Turner, M., Walters, A. E., Cunningham, C. N., Bauer, P. H., Downward, J. & Tybulewicz, V. L. (1996). Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. *Oncogene* 13, 2595–2605.
- Deng, L., Nagano-Fujii, M., Tanaka, M., Nomura-Takigawa, Y., Ikeda, M., Kato, N., Sada, K. & Hotta, H. (2006). NS3 protein of hepatitis C virus associates with the tumor suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. *J Gen Virol* 87, 1703–1713.
- Doi, H., Apichartpiyakul, C., Ohba, K. I., Mizokami, M. & Hotta, H. (1996). Hepatitis C virus (HCV) subtype prevalence in Chiang Mai, Thailand, and identification of novel subtypes of HCV major type 6. *J Clin Microbiol* 34, 569–574.
- Evans, M. J., Rice, C. M. & Goff, S. P. (2004). Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. *Proc Natl Acad Sci U S A* 101, 13038–13043.
- Gale, M., Jr, Blakely, C. M., Kwieciszewski, B., Tan, S. L., Dossett, M., Tang, N. M., Korth, M. J., Polyak, S. J., Gretch, D. R. & Katze, M. G. (1998). Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. *Mol Cell Biol* 18, 5208–5218.
- Gao, J., Zoller, K. E., Ginsberg, M. H., Brugge, J. S. & Shattil, S. J. (1997). Regulation of the pp72^{src} protein tyrosine kinase by platelet integrin $\alpha_{IIb}\beta_3$. *EMBO J* 16, 6414–6425.
- Gao, L., Aizaki, H., He, J. W. & Lai, M. M. (2004). Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. *J Virol* 78, 3480–3488.
- Ghosh, A. K., Majumder, M., Steele, R., Yaciuk, P., Chrivia, J., Ray, R. & Ray, R. B. (2000). Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. *J Biol Chem* 275, 7184–7188.
- Goodman, P. A., Wood, C. M., Vassilev, A., Mao, C. & Uckun, F. M. (2001). Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. *Oncogene* 20, 3969–3978.
- Hamamoto, I., Nishimura, Y., Okamoto, T., Aizaki, H., Liu, M., Mori, M., Abe, T., Suzuki, T., Lai, M. M. C. & other authors (2005). Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. *J Virol* 79, 13473–13482.
- He, Y., Nakao, H., Tan, S. L., Polyak, S. J., Neddermann, P., Vijaysri, S., Jacobs, B. L. & Katze, M. G. (2002). Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. *J Virol* 76, 9207–9217.

- Hidajat, R., Nagano-Fujii, M., Deng, L., Tanaka, M., Takigawa, Y., Kitazawa, S. & Hotta, H. (2005). Hepatitis C virus NS3 protein interacts with ELKS- δ and ELKS- α , members of a novel protein family involved in intracellular transport and secretory pathways. *J Gen Virol* 86, 2197–2208.
- Kaneko, T., Tanji, Y., Satoh, S., Hijikata, M., Asabe, S., Kimura, K. & Shimotohno, K. (1994). Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. *Biochem Biophys Res Commun* 205, 320–326.
- Kurosaki, T., Johnson, S. A., Pao, L., Sada, K., Yamamura, H. & Cambier, J. C. (1995). Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. *J Exp Med* 182, 1815–1823.
- Law, C. L., Chandran, K. A., Sidorenko, S. P. & Clark, E. A. (1996). Phospholipase C- γ 1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. *Mol Cell Biol* 16, 1305–1315.
- Li, J. & Sidell, N. (2005). Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. *Int J Cancer* 117, 14–20.
- Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R. & other authors (2005). Complete replication of hepatitis C virus in cell culture. *Science* 309, 623–626.
- Lohmann, V., Korner, F., Dobierzewska, A. & Bartenschlager, R. (2001). Mutations in hepatitis C virus RNAs conferring cell culture adaptation. *J Virol* 75, 1437–1449.
- Macdonald, A. & Harris, M. (2004). Hepatitis C virus NS5A: tales of a promiscuous protein. *J Gen Virol* 85, 2485–2502.
- Macdonald, A., Crowder, K., Street, A., McCormick, C. & Harris, M. (2004). The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. *J Gen Virol* 85, 721–729.
- Maeda, N., Watanabe, M., Okamoto, S., Kanai, T., Yamada, T., Hata, J., Hozumi, N., Katsume, A., Nuriya, H. & other authors (2004). Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone. *Liver Int* 24, 259–267.
- Majumder, M., Ghosh, A. K., Steele, R., Ray, R. & Ray, R. B. (2001). Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. *J Virol* 75, 1401–1407.
- Mellor, J., Holmes, E. C., Jarvis, L. M., Yap, P. L. & Simmonds, P. (1995). Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. *J Gen Virol* 76, 2493–2507.
- Miah, S. M., Sada, K., Tuazon, P. T., Ling, J., Maeno, K., Kyo, S., Qu, X., Tohyama, Y., Traugh, J. A. & Yamamura, H. (2004). Activation of Syk protein tyrosine kinase in response to osmotic stress requires the interaction with p21-activated protein kinase Pak2/ γ -PAK. *Mol Cell Biol* 24, 71–83.
- Miyazawa, Y., Atsuzawa, K., Usuda, N., Watashi, K., Hishiki, T., Zayas, M., Bartenschlager, R., Wakita, T., Hijikata, M. & Shimotohno, K. (2007). The lipid droplet is an important organelle for hepatitis C virus production. *Nat Cell Biol* 9, 1089–1097.
- Muramatsu, S., Ishido, S., Fujita, T., Itoh, M. & Hotta, H. (1997). Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization. *J Virol* 71, 4954–4961.
- Okamoto, K., Moriishi, K., Miyamura, T. & Matsuura, Y. (2004). Intramembrane proteolysis and endoplasmic reticulum retention of hepatitis C virus core protein. *J Virol* 78, 6370–6380.
- Poole, A., Gibbins, J. M., Turner, M., van Vugt, M. J., van de Winkel, J. G., Saito, T., Tybulewicz, V. L. & Watson, S. P. (1997). The Fc receptor γ -chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. *EMBO J* 16, 2333–2341.
- Qadri, I., Iwahashi, M. & Simon, F. (2002). Hepatitis C virus NS5A protein binds TBP and p53, inhibiting their DNA binding and p53 interactions with TBP and ERCC3. *Biochim Biophys Acta* 1592, 193–204.
- Reed, K. E. & Rice, C. M. (2000). Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. *Curr Top Microbiol Immunol* 242, 55–84.
- Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., Gojobori, T., Maertens, G., Mizokami, M. & other authors (1998). Classification, nomenclature, and database development for hepatitis C virus (HCV) and related virus: proposals for standardization. *Arch Virol* 143, 2493–2503.
- Sada, K., Zhang, J. & Siraganian, R. P. (2000). Point mutation of a tyrosine in the linker region of Syk results in a gain of function. *J Immunol* 164, 338–344.
- Sada, K., Takano, T., Yanagi, S. & Yamamura, H. (2001). Structure and function of Syk protein-tyrosine kinase. *J Biochem* 130, 177–186.
- Schneider, F. & Kieser, A. (2004). A novel assay to quantify cell death after transient expression of apoptotic genes in B- and T-lymphocytes. *J Immunol Methods* 292, 165–174.
- Shi, S. T., Polyak, S. J., Tu, H., Taylor, D. R., Gretch, D. R. & Lai, M. M. (2002). Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* 292, 198–210.
- Shiue, L., Green, J., Green, O. M., Karas, J. L., Morgenstern, J. P., Ram, M. K., Taylor, M. K., Zoller, M. J., Zydowsky, L. D. & other authors (1995). Interaction of p72^{NS5A} with the γ and β subunits of the high-affinity receptor for immunoglobulin E, Fc ϵ RI. *Mol Cell Biol* 15, 272–281.
- Simon, M., Vanes, L., Geahlen, R. L. & Tybulewicz, V. L. (2005). Distinct roles for the linker region tyrosines of Syk in Fc ϵ RI signaling in primary mast cells. *J Biol Chem* 280, 4510–4517.
- Song, J., Fujii, M., Wang, F., Itoh, M. & Hotta, H. (1999). The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. *J Gen Virol* 80, 879–886.
- Street, A., Macdonald, A., Crowder, K. & Harris, M. (2004). The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. *J Biol Chem* 279, 12232–12241.
- Taguchi, T., Nagano-Fujii, M., Akutsu, M., Kadoya, H., Ohgimoto, S., Ishido, S. & Hotta, H. (2004). Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. *J Gen Virol* 85, 959–969.
- Takigawa, Y., Nagano-Fujii, M., Deng, L., Hidajat, R., Tanaka, M., Mizuta, H. & Hotta, H. (2004). Suppression of hepatitis C virus replication by RNA interference directed against the NS3 and NS5B regions of the viral genome. *Microbiol Immunol* 48, 591–598.
- Tan, S. L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P., Jacobs, B. L., Mayer, B. J. & Katze, M. G. (1999). NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. *Proc Natl Acad Sci U S A* 96, 5533–5538.
- Taniguchi, T., Kobayashi, T., Kondo, J., Takahashi, K., Nakamura, H., Suzuki, J., Nagai, K., Yamada, T., Nakamura, S. & Yamamura, H. (1991). Molecular cloning of a porcine gene *syk* that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. *J Biol Chem* 266, 15790–15796.

- Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. (2005). Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. *Nature* **435**, 374–379.
- Tsuchida, S., Yanagi, S., Inatome, R., Ding, J., Hermann, P., Tsujimura, T., Matsui, T. & Yamamura, H. (2000). Purification of a 72-kDa protein-tyrosine kinase from rat liver and its identification as Syk: involvement of Syk in signaling events of hepatocytes. *J Biochem* **127**, 321–327.
- Turner, M., Mee, P. J., Costello, P. S., Williams, O., Price, A. A., Duddy, L. P., Furlong, M. T., Geahlen, R. L. & Tybulewicz, V. L. (1995). Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. *Nature* **378**, 298–302.
- Turner, M., Schweighoffer, E., Colucci, F., Di Santo, J. P. & Tybulewicz, V. L. (2000). Tyrosine kinase SYK: essential functions for immunoreceptor signalling. *Immunol Today* **21**, 148–154.
- Ulanova, M., Puttagunta, L., Marcet-Palacios, M., Duszyk, M., Steinhoff, U., Duta, F., Kim, M. K., Indik, Z. K., Schreiber, A. D. & Befus, A. D. (2005). Syk tyrosine kinase participates in β 1-integrin signaling and inflammatory responses in airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol* **288**, L497–L507.
- Wang, S., Ding, Y. B., Chen, G. Y., Xia, J. G. & Wu, Z. Y. (2004). Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. *World J Gastroenterol* **10**, 1815–1818.
- Weiss, A. & Littman, D. R. (1994). Signal transduction by lymphocyte antigen receptors. *Cell* **76**, 263–274.
- Wienands, J., Larbolette, O. & Reth, M. (1996). Evidence for a preformed transducer complex organized by the B cell antigen receptor. *Proc Natl Acad Sci U S A* **93**, 7865–7870.
- Yamada, T., Fujieda, S., Yanagi, S., Yamamura, H., Inatome, R., Sunaga, H. & Saito, H. (2001). Protein-tyrosine kinase Syk expressed in human nasal fibroblasts and its effect on RANTES production. *J Immunol* **166**, 538–543.
- Yanagi, S., Kurosaki, T. & Yamamura, H. (1995). The structure and function of nonreceptor tyrosine kinase p72^{SYK} expressed in hematopoietic cells. *Cell Signal* **7**, 185–193.
- Yanagi, S., Inatome, R., Ding, J., Kitaguchi, H., Tybulewicz, V. L. & Yamamura, H. (2001). Syk expression in endothelial cells and their morphologic defects in embryonic Syk-deficient mice. *Blood* **98**, 2869–2871.
- Yasui, K., Wakita, T., Tsukiyama-Kohara, K., Funahashi, S. I., Ichikawa, M., Kajita, T., Moradpour, D., Wands, J. R. & Kohara, M. (1998). The native form and maturation process of hepatitis C virus core protein. *J Virol* **72**, 6048–6055.
- Yuan, Y., Mendez, R., Sahin, A. & Dai, J. L. (2001). Hypermethylation leads to silencing of the SYK gene in human breast cancer. *Cancer Res* **61**, 5558–5561.
- Yuan, Y., Wang, J., Li, M., Yan, Z., Zhang, C. & Dai, J. L. (2006). Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. *Clin Cancer Res* **12**, 6687–6695.
- Zech, B., Kurtenbach, A., Krieger, N., Strand, D., Blencke, S., Morbitzer, M., Salassidis, K., Cotten, M., Wissing, J. & other authors (2003). Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. *J Gen Virol* **84**, 555–560.
- Zhang, J., Berenstein, E. & Siraganian, R. P. (2002). Phosphorylation of Tyr342 in the linker region of Syk is critical for Fc- ϵ RI signaling in mast cells. *Mol Cell Biol* **22**, 8144–8154.

Risk of Hepatocellular Carcinoma and Secondary Structure of Hepatitis C Virus (HCV) NS3 Protein Amino-Terminus, in Patients Infected with HCV Subtype 1b

Yuko Nishise,¹ Takafumi Saito,¹ Kazuhiko Sugahara,¹ Jun-itsu Ito,¹ Koji Saito,¹ Hitoshi Togashi,¹ Motoko Nagano-Fujii,² Hak Hotta,² and Sumio Kawata¹

¹Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, and ²Division of Microbiology, Kobe University Graduate School of Medicine, Hyogo, Japan

We conducted a retrospective study of 65 patients with chronic hepatitis C, to determine whether the secondary structure of the amino-terminal 120 residues of the hepatitis C virus (HCV) NS3 protein is associated with an increased risk of development of hepatocellular carcinoma (HCC). The cumulative incidence of HCC was highest among patients infected with group B HCV-1b, wherein the risk of HCC significantly increased compared with that among patients infected with group A (hazard ratio, 4.95 [95% CI, 1.43–17.11]) after adjustment for age and histological stage. This HCV-1b grouping may be a useful marker for detecting the risk of development of HCC.

Hepatocellular carcinoma (HCC) is a common malignancy, and the mortality associated with it is increasing in Japan [1]. The 3 major categories of risk factors that appear to influence the incidence of HCC are host, viral, and environmental factors. Epidemiologic and clinical studies have shown that chronic hepatitis C virus (HCV) infection is a major cause of HCC [2].

At present, HCV is classified into at least 6 genotypes and >60 subtypes [3, 4]. HCV subtype 1b (HCV-1b) is most common in Asian countries, including Japan [5]. Patients infected with HCV-1b have a greater risk of progression to HCC than do those infected with other subtypes [6]. However, it remains unclear whether all HCV strains are associated with HCC to an equal degree.

We have been interested in the possible involvement of the HCV NS3 region in hepatocarcinogenesis. It has been reported that an amino-terminal portion of NS3 (aa 1027–1295 and aa 1008–1246) has the potential to transform NIH 3T3 and rat fibroblast cells [7, 8]. Moreover, studies have reported (1) that an amino-terminal portion of NS3 (aa 1027–1459) renders NIH 3T3 cells more resistant to DNA damage–induced apoptosis [9, 10], which is thought to be a prerequisite for the malignant transformation of cells, and (2) that NS3 interacts differentially, in a sequence-dependent manner, with the p53 tumor suppressor [11].

Recently, we reported that HCV-1b strains can be classified into different groups based on the secondary structure of an amino-terminal portion of the NS3 protein and that group B strains are more prevalent among patients with HCC [12]. These results suggest the possibility that HCV-1b strains of group B cause HCC more frequently than do group A strains. Using a retrospective cohort study design, we precisely assessed the possible association between the HCV-1b NS3-protein group and the risk of development of HCC.

Patients and methods. This retrospective cohort study enrolled outpatients infected with HCV-1b, who were referred from general medical or hepatology clinics to the Yamagata University Hospital, to further investigate their liver status. They all had been diagnosed histologically as having chronic hepatitis or cirrhosis. Patients with alcohol-related liver injury or autoimmune hepatitis or who were positive for hepatitis B surface antigen were excluded. Furthermore, patients who were followed up for <12 months were excluded, to rule out the possibility that the cancer was present at the start of the study. Twenty patients were excluded because samples available for group analysis were inadequate. We consequently examined 65 patients. Observation began in October 1981 and ended in December 2005. The baseline condition was considered to be the initial histologic diagnosis, and the end points were considered to be either (1) development of HCC or (2) last ultrasonogram (US) or computed tomogram (CT) without a diagnosis of HCC. At baseline, none of the patients had a diagnosis of HCC, on the basis of screening tests using US, CT,

Received 18 February 2007; accepted 26 April 2007; electronically published 23 August 2007.

Potential conflicts of interest: none reported.

Presented in part: 57th annual meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 27–31 October 2006 (abstract 862).

Financial support: 21st Century Center of Excellence Program of the Japan Society for the Promotion of Science (grant-in-aid F-1 to S.K. and T.S.); Special Scientific Research from Japan's Ministry of Education, Culture, Sports, Science and Technology (grant-in-aid 16160101 to S.K., T.S., and H.T.).

Reprints or correspondence: Dr. Y. Nishise, Dept. of Gastroenterology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata, Yamagata 990-9585, Japan (ynishise-gi@umin.ac.jp).

The Journal of Infectious Diseases 2007;196:1006–9

© 2007 by the Infectious Diseases Society of America. All rights reserved.

0022-1899/2007/19607-0010\$15.00

DOI: 10.1086/521309

Table 1. Baseline characteristics of patients infected with group A, B, and C strains of HCV.

Characteristic	Group A (n = 18)	Group B (n = 44)	Group C (n = 3)	P
Age				
≤55 years	11 (61)	18 (41)	1 (33)	.37 ^a
>55 years	7 (39)	26 (59)	2 (67)	
Sex				
Male	13 (72)	21 (48)	2 (67)	.20 ^a
Female	5 (28)	23 (52)	1 (33)	
Stage of liver fibrosis				
F1 or F2	10 (56)	22 (50)	3 (100)	.30 ^a
F3 or F4	8 (44)	22 (50)	0 (0)	
Grade of inflammatory activity				
A1 or A2	13 (72)	28 (64)	3 (100)	.52 ^a
A3	5 (28)	16 (36)	0 (0)	
Alanine aminotransferase level				
≤100 IU/L	9 (50)	27 (61)	0 (0)	.11 ^a
>100 IU/L	9 (50)	17 (39)	3 (100)	
Time since diagnosis of chronic liver injury, years				
Median	1.3	0.7	1.5	.51 ^b
Range	0.2–9.3	0.3–8.5	0.5–1.5	
Time since blood transfusion, ^c years				
Median	26.8	26.967 ^d
Range	5.7–35.6	5.5–36.0		

NOTE.Data are no. (%) of subjects, unless otherwise indicated.

^a By Fisher's exact test.

^b By Kruskal-Wallis test.

^c Based on data from those patients who had a history of blood transfusion, including 10 infected with group A strains and 17 infected with group B strains.

^d By Mann-Whitney test.

or serum α -fetoprotein (AFP) level. None of the patients without HCC died during the follow-up period. All of the patients underwent screening examination for HCC, by either US or CT, at least once every 6 months, as well as blood testing, including testing for AFP, every 1 or 2 months. None of the personnel involved in the decision to screen and in selection of participants in the study were aware of the group status. There was no evident difference in screening frequency among the groups. The cirrhotic patients at baseline were all in a state of Child class A, which means that the clinically evaluated severity of liver disease was mild. The HCV genotype was determined by reverse-transcription polymerase chain reaction (RT-PCR) using genotype-specific primers [13].

On the basis of the secondary structure of NS3 protein, the HCV-1b isolates from all patients were classified further—into group A, group B, and an indeterminate group, group C, as reported elsewhere [12]. After October 2001, stored frozen samples collected during the follow-up period were used to determine the group. To identify whether the group shifted to another group during the infection period, the group of 8 patients

was examined by use of paired serum samples from each of them.

Histological findings were scored to determine the stage of liver fibrosis and the grade of inflammatory activity, according to the classification system of Desmet et al. [14], by institutional pathologists who were blinded to the subjects' respective subgroup classifications. The stage of fibrosis was assessed as ranging from stage F0 (no fibrosis) to F4 (cirrhosis), and the grade of inflammatory activity was scored from grade A0 (minimal) to grade A3 (severe).

Written informed consent was obtained from all the participants. The study was approved by the Ethics Committee of Yamagata University.

The characteristics of the groups of patients were compared by use of Fisher's exact test, Mann-Whitney test, or Kruskal-Wallis test. Cumulative incidence curves were estimated by use of the Kaplan-Meier method; differences between the groups were assessed by use of the log-rank test. The risk of development of HCC was evaluated by use of the hazard ratio (HR) and its 95% confidence interval (CI), which were estimated by

use of the Cox proportional hazard model. The following 5 variables at baseline and the average HCV RNA level during the follow-up period were analyzed to assess potential confounding for liver carcinogenesis: age (≤ 55 years or > 55 years), sex (male or female), stage of liver fibrosis (F1/F2 or F3/F4), grade of inflammatory activity (A1/A2 or A3), alanine aminotransferase level (≤ 100 IU/L or > 100 IU/L), and HCV RNA level (low or high). The serum HCV RNA level was designated as a high viral load when it was either $> 10^6$ equivalents/mL, on the basis of branched DNA probe assay, or $> 10^5$ copies/mL, on the basis of combined RT-PCR assay (Amplicor-HCV monitor assay). Also, patients who received interferon therapy, which is effective against HCV infection and is known to reduce the risk of development of HCC in patients with chronic hepatitis C, were compared with those who had not received it [15].

It was difficult to clarify the time when some of the patients in the present study became infected with HCV. Therefore, we evaluated 2 factors as a proxy of the infection period before enrollment: (1) time since diagnosis of chronic liver injury and (2) time since blood transfusion in 27 patients who had a history of transfusion. The proportional hazard assumption was checked for all covariates, and no relevant violations were found. We used SAS statistical software (version 8.2; SAS Institute, Inc.) for the analyses. $P < .05$ was considered to be statistically significant.

Results. Of the 65 HCV-1b isolates analyzed, 18 were classified as group A, 44 as group B, and 3 as group C. Baseline characteristics of the patients infected with group A, B, and C strains are summarized in table 1. For the factors listed in the table, there were no significant differences between the groups. The HCV RNA level also did not differ significantly between the 3 groups ($P = .158$): the proportions of patients with a high viral load were 67%, 86%, and 100% in those infected with group A, B, and C strains, respectively. The median follow-up period was 12.8 years (range, 1.0–19.5 years). The subgroups that had been determined on the basis of 8 paired serum samples did not shift to another group during a mean interval of 11 years. During the follow-up period, HCC developed in 3 (17%) of the patients infected with group A strains, in 28 (64%) of those infected with group B strains, and in 0 of those infected with group C strains. In all the cases, HCC was a solitary nodule or comprised double nodules with diameters ≤ 3.0 cm. Forty-one patients (63%) received interferon therapy at least once during the follow-up period. The proportion of patients infected with group A strains who received treatment was not significantly different from the proportion of patients infected with B strains who received treatment (72% and 57%, respectively; $P = .39$), and the patients who received treatment were all nonsustained virologic responders. Therefore, in the present study, the effect that treatment had on the development of HCC was considered to be small.

Figure 1 depicts the cumulative incidence of HCC (determined by the Kaplan-Meier method) in the 3 groups. The 10-year cumulative incidences for patients infected with group A strains and for those infected with group B strains were 0.16 (95% CI, 0.00–0.37) and 0.43 (95% CI, 0.28–0.58), respectively; the 15-year rates for these 2 groups were 0.16 (95% CI, 0.00–0.37) and 0.72 (95% CI, 0.54–0.90), respectively. Cumulative incidence differed significantly between patients infected with group A strains and those infected with group B strains ($P < .01$, by log-rank test).

For estimation of risk of development of HCC, we focused on group A strains and group B strains, because the number of group C strains was too small to allow accurate evaluation of this association. The crude HR for development of HCC among patients infected with group B strains (when the crude HR among patients infected with group A strains was considered to be the reference) was 4.92 (95% CI, 1.48–16.32), and group B strains were significantly associated with HCC after adjustment for each potential confounding factor: HR, 5.15 (95% CI, 1.52–17.38); HR, 5.79 (95% CI, 1.70–19.77); HR, 5.10 (95% CI, 1.53–17.04); HR, 4.05 (95% CI, 1.21–13.56); and HR, 5.77 (95% CI, 1.68–19.83) for age, sex, grade of inflammatory activity, stage of fibrosis, and HCV RNA level, respectively. On the basis of the results of 31 cases of development of HCC, we included 2 important factors—namely, age and




Figure 1. Cumulative incidence of hepatocellular carcinoma (HCC) among 65 patients infected with hepatitis C virus subtype 1b (HCV-1b), estimated by use of the Kaplan-Meier method. The graph shows Kaplan-Meier curves for patients in groups A ($n = 18$) (dotted line), B ($n = 44$) (solid line), and C ($n = 3$) (dashed line). The cumulative incidence of HCC differed significantly between the 3 groups ($P < .01$, by log-rank test).

histologic stage—in the multivariate model; after adjustment for these 2 factors, the risk was significantly greater among the patients infected with group B strains (HR, 4.95 [95% CI, 1.43–17.11]).

Discussion. The findings of the present study suggest that the secondary structure of the amino-terminal 120 residues of the HCV NS3 protein may be independently associated with the risk of development of HCC. The mechanism underlying the relationship between hepatocarcinogenesis and sequence diversity remains unclear. It has been speculated that the difference in the secondary structure of NS3 causally associates with HCC, which reflects a conformational difference that might consequently affect interaction with the p53 tumor-suppressor gene [11]. However, there is another possibility—that the NS3-protein group B strains exert oncogenic function via a mechanism independent of interaction with p53. Moreover, we cannot exclude the possibility that the other biological functions of NS3, such as serine protease activity and antiapoptotic capacity, vary between different groups. In a previous study, which included 35 (54%) of the patients in the present study, we analyzed the amino acid sequences of the HCV isolate from patients with or without HCC and, among the majority of isolates from patients with HCC, did not find, at the primary-structure level, any particular residue that might be contributing to HCC [12]. Further experimental studies are necessary to elucidate these issues.

Long-term chronic inflammation is considered to be related to carcinogenesis. Unfortunately, it was difficult, in some patients in the present study, both to determine when they became infected with HCV and to evaluate the true duration of their infection. We chose, as the baseline, the time when liver biopsy was performed, because histologic characteristics are strong factors for development of HCC [15]. Although the presumed infection period before enrollment was not significantly different between the groups, it should be noted that there might have been unmeasured confounding, because of the limitation posed by the present study's lack of data with respect to true disease-inception status.

In conclusion, the present study shows that the long-term cumulative incidence of HCC in patients infected with HCV group A is significantly different from that in patients infected with HCV group B—and that, after adjustment for age and stage of fibrosis, the latter patients have a markedly increased HR. These findings suggest that HCV-1b grouping, based on the secondary structure of an amino-terminal portion of the NS3 protein, is a potential marker for a high risk of development of HCC in patients with chronic hepatitis C. It is important to further test and replicate the present study's re-

sults, in other populations and in a larger number of subjects who have a defined time point of infection, such as blood-transfusion recipients.

Acknowledgment

We thank L. Shao for helpful comments.

References

1. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. *Gastroenterology* 2004;127:S17–26.
2. Kiyosawa K, Sodeyama E, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *Hepatology* 1990;12:671–5.
3. Doi H, Apichartpiyakul C, Ohba KI, Mizokami M, Hotta H. Hepatitis C virus (HCV) subtype prevalence in Chiang Mai, Thailand, and identification of novel subtypes of HCV major type 6. *J Clin Microbiol* 1996;34:569–74.
4. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. *J Gen Virol* 1995;76:2493–507.
5. Hotta H, Kemapunmanus M, Apichartpiyakul C, Soetjijto, Handajani R, Barzaga NG. Differential distribution of hepatitis C virus subtypes in Asia: comparative study among Thailand, Indonesia, the Philippines and Japan. *Southeast Asian J Trop Med Public Health* 1997;28 (Suppl 3):23–31.
6. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. *Hepatology* 1997;25:754–8.
7. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. *J Virol* 1995;69:3893–6.
8. Zemel R, Gerechet S, Greif H, et al. Cell transformation induced by hepatitis C virus NS3 serine protease. *J Viral Hepat* 2001;8:96–102.
9. Fujita T, Ishido S, Muramatsu S, Itoh M, Hotta H. Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. *Biochem Biophys Res Commun* 1996;229:825–31.
10. Muramatsu S, Ishido S, Fujita T, Itoh M, Hotta H. Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization. *J Virol* 1997;71:4954–61.
11. Ishido S, Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. *FEBS Lett* 1998;438:258–62.
12. Ogata S, Florese RH, Nagano-Fujii M, et al. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. *J Clin Microbiol* 2003;41:2835–41.
13. Okamoto H, Kurai K, Okada S, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. *Virology* 1992;188:331–41.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 1994;19:1513–20.
15. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. *Ann Intern Med* 1998;129:94–9.



Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C

Takanori Yokota ^{a,*}, Sayuki Iijima ^b, Takayuki Kubodera ^{a,c}, Koji Ishii ^d,
Yuko Katakai ^e, Naohide Ageyama ^b, Yingwei Chen ^a, Young-Jung Lee ^b,
Toshinori Unno ^a, Kazutaka Nishina ^a, Yuki Iwasaki ^b, Noboru Maki ^f,
Hidehiro Mizusawa ^{a,c}, Hirofumi Akari ^{b,*}

^a Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University,
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

^b Laboratory of Disease Control, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1 Hachimandai, Tsukuba 305-0843, Japan

^c 21 century COE Program on Brain Integration and its Disorders, Japan

^d Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan

^e Corporation for Production and Research of Laboratory Primates, 1 Hachimandai, Tsukuba 305-0843, Japan

^f Advanced Life Science Institute, Inc, 2-10-23 Maruyamada, Wako 351-0112, Japan

Received 20 June 2007

Available online 16 July 2007

Abstract

RNA interference (RNAi) represents a new technology which could offer potential applications for the therapeutics of human diseases. RNAi-mediated therapy has recently been shown to be effective toward infectious diseases in *in vitro* and rodent models, however, it remains unclear whether RNAi therapy with systemic application could be effective in primates. In this study, we examined if RNAi therapy could be effective toward infectious diseases by using a non-human primate surrogate model for hepatitis C. Administration into marmosets of cationic liposome-encapsulated siRNA (CL-siRNA) for GB virus B (GBV-B), which is most closely related to hepatitis C virus, repressed GBV-B replication in a dose-dependent manner. Especially, 5 mg/kg of the CL-siRNA completely inhibited the viral replication. Since the serum interferons (IFNs) were induced by CL-siRNA *in vivo*, inhibition of viral regulation by anti-GBV-B CL-siRNA may include an antiviral effect of IFN. However, contribution of induced IFN may be partial, since the control CL-siRNA which induced a stronger IFN response than GBV-B CL-siRNA could only delay the viral replication. Our results suggest the feasibility of systemic administration of CL-siRNA as an antiviral strategy.

© 2007 Published by Elsevier Inc.

Keywords: siRNA; Hepatitis C; Marmoset; Interferon; GB virus B

RNA interference is a powerful tool for silencing gene expression and has spurred considerable interest in its experimental and therapeutic potential. RNAi has been characterized as a cellular process of post-transcriptional gene silencing. An RNaseIII-like enzyme, called Dicer, cleaves double stranded RNA (dsRNA) into 21–23 nucle-

otide RNA duplex, termed small interfering RNAs (siRNAs). siRNAs are unwound in the RNA-induced-silencing-complex (RISC), and single-stranded siRNAs then act as a guide to substrate selection, leading to the cleavage of a homologous target RNA molecule [1].

Hepatitis C virus (HCV) infection contributes significantly to human morbidity and mortality worldwide. It is estimated that 40–60% of infected individuals progress to chronic liver disease, and many of these patients develop liver cirrhosis and hepatocellular carcinoma [2]. Currently,

* Corresponding authors.

E-mail addresses: tak-yokota.nuro@tmd.ac.jp (T. Yokota), akari@nibio.go.jp (H. Akari).

the only treatment available for patients with chronic HCV infections is combinational therapy with interferon (IFN) and ribavirin. The standard therapy is only effective for approximately 50% of patients with chronic HCV hepatitis [3]. Therefore, there is a great need for less complicated and more generally efficient therapeutics for HCV infection.

We and others reported that the synthetic siRNA and the siRNA-expressing adenovirus targeting 5'-UTR of HCV genome efficiently and specifically inhibited the HCV replication *in vitro* [4–6]. Other than humans, only chimpanzees can be productively infected by HCV. Together with ethical issues it has become increasingly difficult to access chimpanzees for experimental studies. The new world monkeys, tamarins and marmosets, undergo hepatitis upon infection with the GBV-B, which is most closely related to HCV. The significant similarity between HCV and GBV-B at the genomic and biochemical levels led to the proposal of the GBV-B/monkey system as a good surrogate model for hepatitis C [7,8]. Taking advantage of this non-human primate surrogate model, we investigated the feasibility of siRNA-mediated therapy against infectious diseases caused by pathogenic viruses.

Materials and methods

Preparation of siRNA. The sequence of siRNA for GBV-B was cucguagaccguagcacaU dTdT in the sense strand and augugcuacggucucagagdTdT in the antisense strand which was designed to target the GBV-B RNA (Fig. 1). The sequence of control siRNA for




Fig. 2. Effects of the siRNA oligonucleotides on expression of GBV-B-reporter gene in culture cells (A) and liver of mice (B).

experiments of Fig. 2A and B was uua ugc cga ucg cgU cac a dTdT in the sense strand and ugu gac gcg auc ggc aua a dTdT in the antisense strand which was designed to target beta-galactosidase RNA, and that for experiments of Figs. 3 and 4 was gct atg aaa cga tat ggg c dTdT in the sense strand and g ccc aua ucg uuu cau ugc dTdT in the antisense strand which was designed to target *firefly*-luciferase RNA. siRNA oligonucleotides were chemically synthesized and purified by reverse-phase high-performance liquid chromatography, while the unconjugated RNA oligonucleotides were purified by anion-exchange high-performance liquid chromatography. The sense and antisense strands were annealed at 95 °C for 1 min followed by slow cooling in RNase free water. Positively charged liposomes containing cationic lipid analogue were synthesized at Nippon Shinyaku Co., as described previously [9]. To prepare CL-siRNA,




Fig. 1. Predicted secondary structure of the 5'-untranslated region around the target site (italic) in the HCV and GBV-B genome (nucleotide 114–137 and 285–359 of HCV, and 263–255 and 390–467 of GBV-B), and the sense sequences of siRNA.

annealed siRNA was added to the same volume of liposome solution with sonication. The ratio of oligonucleotide to LIC-101 was 1:16 (w/w).

Cells culture and transfection. The human embryonic kidney cell line, 293 T, was maintained in Dulbecco's modified minimal essential medium (Sigma, St. Louis, Missouri) supplemented with 10% fetal calf serum at 37 °C under 5% CO₂. Transfections of the siRNA oligonucleotides and the plasmids were performed in 24-well plates using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions. GBV-B-RNA-reporter gene vector, pGBV-B-RLuc, was used as a target, which expressed mRNA consisting of GBV-B 5'-untranslated region and upstream part of the core region (nucleotide 1–377) connected with upstream of *renilla* luciferase (RLuc) gene. Fifty nanograms of the pGBV-B-RLuc and 2 and 25 nM of siRNA were transiently transfected with 20 ng of *firefly* luciferase (FLuc)-expressing plasmid (pRL-RSV, Promega). The RLuc activity was adjusted by the FLuc activity, to normalize the transfection efficiency.

Luciferase assays. Luciferase activities were quantified with a luminometer (Lumat LB9501, Promega) using the Bright-Glo Luciferase Assay System (Promega). Assays were performed in triplicate and the results expressed as means ± SD as percentages of controls.

Animals. Male BALB/c or ICR mice, 9 weeks of age, were obtained from CLEA Japan and subject to a 2-week quarantine and acclimation period before use. Male juvenile common marmosets (*Callithrix jacchus*) were housed in individual cages at the Tsukuba Primate Medical Center. All animal studies were conducted in accordance with the protocols of experimental procedures which were approved by the Animal Welfare and Animal Care Committee of the National Institute of Biomedical Innovation and Tokyo Medical and Dental University.

In vivo efficacy experiments in mice. For the *in vivo* delivery of the siRNA to the liver of mice and monkeys, we used a novel cationic liposome that was synthesized by Nippon Shinyaku Co., Ltd. This cationic liposome was reported to be a good vehicle for the delivery of nucleic acid polymers and siRNAs to the liver when it was administered intravenously [9,10] or to the bladder by intravesical administration [11]. For the delivery of plasmid DNA to the liver of mice we used the hydrodynamic injection method in which a large volume of nucleotides solution was rapidly injected from tail vein [12]. *Three mice for each group were examined.* 5.0 mg/kg GBV-B or control CL-siRNA was administered as a regular intravenous injection from the tail vein in 0.2 ml 10% maltose over a period of 1–3 s. Three minutes later, the 50 µg of the pGBV-B-RLuc and 20 µg of pRL-RSV plasmids in a volume equivalent to 5% of the body weight were rapidly injected in 3–5 s

into the mouse tail vein according to the hydrodynamic injection method. Phosphate buffer saline (PBS) was used as a carrier solution for injection. Successful injection was monitored when the conjunctiva of mouse became transiently anemic and confirmed by the luciferase activity in the liver.

In vivo efficacy experiments in monkeys. Negative control (n = 2; with or without control siRNA) and treatment group (n = 3; 1.0, 2.5 and 5.0 mg/kg of anti-GBV-B siRNA) were employed in this study. GBV-B-infectious serum obtained from a tamarin [8] was intrahepatically inoculated with the GBV-B RNA. The siRNA to GBV-B and control siRNA formulated by the cationic liposome, or just 10% maltose (sham) was administered by standard intravenous injection via the saphenous vein of the marmosets for three days. On the second day, the GBV-B infectious serum (1.3 × 10⁹ viral RNA copies/inoculum) was directly injected to the liver of five marmosets. Blood samples were periodically collected from the femoral vein of the monkeys under anesthetization. GBV-B RNA in plasma from the monkeys was quantified by a real-time, 5' exonuclease PCR (TaqMan) assay using a primer-probe combination that recognized a portion of the GBV-B capsid gene as previously described [8]. The Platelet cell counts were performed at FALCO Biosystems, Co., Ltd.

Measurement of IFNs in mice and monkeys. The siRNA/cationic liposome was injected from tail vein of ICR mice or saphenous vein of the marmosets. Blood samples were taken 3 h after the injection. Mouse IFN-α levels were quantified by using sandwich ELISA kits for mouse IFNs (PBL Biomedical Laboratories, Biosource). Marmoset IFN-α and -γ levels were by using sandwich ELISA kits for human and rhesus macaque IFN, respectively (U-CyTech bioscience) according to the manufacturer's instructions. Assays were performed in duplicate and the results expressed as means ± SD as percentages of controls.

Results

We selected the siRNA-targeting site to the GBV-B genome from its 5'-UTR, the most conservative portion in both GBV-B and HCV genomes [13], to protect the siRNA from escape mutations of the virus [4]. The secondary structures of virus genome RNAs of HCV and GBV-B around the target site are very similar to each other, and the designed siRNA was different from the corresponding sequence of HCV by only two nucleotides (Fig. 1).




Fig. 3. Effect of the GBV-B siRNA/cationic liposome complex on replication of GBV-B in marmosets.




Fig. 4. Side effects of siRNA/cationic liposome complex. (A) Induction of IFN- α was evaluated by measuring mouse serum 3 h after intravenous injection of 1–5 mg/kg GVB-B or control siRNA/cationic liposome complex ($n = 3$). * <0.05 (Student t test). (B) Induction of IFN- α and γ was evaluated by measuring marmoset serum 3 h after intravenous injection of 5 mg/kg GVB-B or control siRNA/cationic liposome complex, respectively ($n = 3$). (C) Peripheral blood platelet was counted in the five marmosets examined in the same experiment shown in Fig. 3.

Effect of siRNA *in vitro* and *in mice*

First, we confirmed the efficient cleavage of GBV-B RNA by the siRNA in 293 T cells. The cells were harvested at 24 h of transfection with pGBV-B-Rluc, pRL-RSV and siRNA oligonucleotides, and internal luciferase activities were measured and ratio of RLuc versus FLuc value was calculated. More than 90% the RLuc activities were inhibited by expressing co-transfected siRNA (Fig. 2A). This result clearly indicated that GBV-B siRNA efficiently inhibited the expression of GBV-B RNA in culture cells.

Next, we investigated the *in vivo* effect of siRNA formulated in the cationic liposome on silencing the viral gene expression in the liver of mice. BALB/c mice were injected

intravenously from the tail vein with GVB-B CL-siRNA followed by hydrodynamically injection of pGBV-B-Rluc and pRL-RSV. We found that intravenously administered GBV-B CL-siRNA efficiently suppressed the expression of GBV-B genome in the liver of mice (Fig. 2B).

Effect of siRNA on GBV-B replication in marmosets

The 1.0, 2.5 and 5.0 mg/kg/day of siRNA to GBV-B, 5.0 mg/kg/day of control siRNA formulated by the cationic liposome, or just 10% maltose (sham) were administered by standard intravenous injections via the saphenous vein of the marmosets for three consecutive days. On the second day, GBV-B infectious serum

(1.3×10^9 viral RNA copies/inoculum) was directly injected to the liver. Before and after the inoculation, GBV-B RNA in the serum was quantified by a real-time, 5' exonuclease PCR. In a sham-administered marmoset, the viral RNA was transiently increased in plasma after infection and the viral load reached to the peak level (3.6×10^7 copies/ml) (Fig. 3). It has been reported that GBV-B infection in marmosets as well as tamarins causes semi-acute viremia which generally ceases within 10–12 weeks post-infection [8,14,15]. This viral kinetics is consistent with the cases of HCV-infected human or chimpanzee, thus it appears to be in vivo characteristics of genus hepativirus where HCV and GBV-B belong to. Virological or immunological implication for the transient viremia is not fully addressed.

In contrast to sham-administered marmoset, we could find that the administration of CL-siRNA significantly delayed or suppressed the replication of GBV-B in a dose-dependent manner; the 5.0 mg/kg CL-siRNA completely suppressed the replication of GBV-B for more than 6 months after the infection (Fig. 3), even though the siRNA was administered only for the initial 3 days. Unexpectedly, the 5.0 mg/kg of control CL-siRNA was also able to delay the virus replication, while the peak level was comparable with that of the untreated monkey (Fig. 3).

Induction of interferons

We evaluated the induction of serum IFN- α by intravenous administration of the siRNA with cationic liposome in mice. IFN- α was induced by CL-siRNA but not by the cationic liposome nor siRNA oligonucleotide alone (data not shown). Induced IFN levels in the sera were dose-dependent and were significantly higher in mice with the control CL-siRNA than those with the GBV-B CL-siRNA (Fig. 4A).

An independent experiment using marmosets showed that single injection of 5.0 mg/kg control CL-siRNA substantially induced the serum interferon (IFN)- α and - γ , whereas the same dose of CL-siRNA induced a minimal level of IFN- α and no detectable level of IFN- γ (Fig. 4B).

In addition, a transient and mild decrease in peripheral blood platelets was more clearly observed in the marmoset treated with 5.0 mg/kg of control than 5.0 mg/kg of GBV-B CL-siRNA (Fig. 4C). There was no other remarkable abnormality related to siRNA administration in biochemical parameters indicating liver dysfunction which include alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and albumin.

Discussion

Many viruses produce some dsRNA as a byproduct of their replication [16], and RNAi serves as an important defense against viruses in plants [17]. Therefore, mammalian viruses have been expected to be a good therapeutic target of RNAi, and indeed, several animal viruses have been successfully inhibited to replicate *in vitro* [18]. Locally

delivered siRNA have proven effective in abrogating infection from respiratory [19–22] and vaginal [23] viruses. Recently, systemically-delivered siRNA in mice has been successfully suppressed the expression of endogenous gene of the liver [24–26]. However, it remains to be ascertained if the RNAi-mediated gene therapy with systemically-delivered siRNA would be applicable to hepatitis virus in non-human primates. In this study, we examined if RNAi therapy could be effective toward infectious diseases by using a non-human primate surrogate model for hepatitis C. Administration into marmosets of CL-siRNA for GBV-B, which is most closely related to hepatitis C virus, repressed GBV-B replication in a dose-dependent manner. Our results suggest the feasibility of systemic administration of CL-siRNA as an antiviral strategy.

The 5.0 mg/kg GBV-B CL-siRNA dramatically inhibited the replication of GBV-B. However, control CL-siRNA also delayed the virus replication. Intravenous injection of siRNA formulated with liposomes was reported to stimulate mammalian immune system [26,27]. In relation to antiviral effect of IFNs, we therefore measured the serum IFN levels. Since the GBV-B siRNA/cationic liposome had less effect in IFN induction than the control but better antiviral effect than the control, it is possible that inhibition of the viral replication by the GBV-B siRNA/cationic liposome complex was at least in part caused by RNA interference. On the other side, it is also likely that IFN locally induced in the marmoset liver contributed the suppression of the viral replication. Because the induced level of mice serum IFN- α by GBV-B CL-siRNA was significant, although it was less than that by control CL-siRNA. Moreover, estimated IFNs level in marmoset serum was minimal but their actual levels might have been more, because the standard IFN in the ELISA was human or rhesus macaque IFN. Therefore, we considered that the antiviral effect of CL-siRNA was made by both RNA interference and induced IFNs.

In therapeutic application of siRNA to humans, general safety is a most important problem. The side effect of CL-siRNA to the liver is thought to consist of direct liver toxicity which is probably caused by its hydrophobic nature and its immuno-stimulatory effect [26–28]. Recently, Zimmermann et al. has reported that siRNA delivered systemically in a cationic liposome, stable nucleic acid lipid particles (SNALP), inhibited endogenous gene expression in the liver of the cynomolgus monkeys, which supports our notion concerning the therapeutic potential of systemically injected siRNA in primates. Although they made excellent chemical modifications to siRNA oligonucleotides to reduce IFN induction, their siRNA complex produced a considerable liver damage with a marked increase of transaminases at the dose (2.5 mg/kg) of maximal suppression effect. This indicated that the therapeutic window of their siRNA complex is overlapped with its toxic window. In contrast, our CL-siRNA induced much less liver damage, since even the 5.0 mg/kg of our CL-siRNA did not show a marked liver damage, but induced a sub-

stantial immune responses. A number of recent studies revealed that siRNA/cationic liposome complex has an immunological effects of siRNAs including the induction of proinflammatory cytokines and type I IFNs (IFN- α and IFN- β) through activation of RNA-sensing immunoreceptors including three members of the Toll-like receptor (TLR) family (TLR3, TLR7 and TLR8) [29]. Detection of siRNA molecules could trigger antiviral innate defense mechanisms including the induction of type I IFNs. In fact, double strand RNA molecule, poly I/C, was reported to eliminate the virus in GBV-B-infected tamarin hepatocytes by activating TLR3 [30,31]. These knowledges lead us to postulate that it is one of sophisticated strategy for siRNA to inhibit hepatitis virus to use this immuno-stimulatory side effect as an antiviral innate defense, only if the systemic side effects are tolerable.

Acknowledgments

We thank members of Corporation for Production and Research of Laboratory Primates for their technical support, N. Enomoto (Yamanashi University) for the invaluable suggestions and encouragements, and S. Arold (CNRS, France) for critical reviewing of the manuscript. RNAs and cationic liposome were supplied by Nippon Shinyaku Co., Ltd. This work was supported by Grants from the Ministry of Education, Science and Culture, Japan (#18390215, T.Y. and H.A.) and from the Ministry of Health, Labor and Welfare, Japan (#2212065, T.Y.; #17200101, H.A.).

References

- [1] G.J. Hannon, RNA interference, *Nature* 418 (2002) 244–251.
- [2] W.R. Kim, The burden of hepatitis C in the United States, *Hepatology* 36 (2002) S30–S34.
- [3] J.M. Mchutchison, Hepatitis C advances in antiviral therapy: what is accepted treatment now? *J. Gastroenterol. Hepatol.* 17 (2002) 431–441.
- [4] T. Yokota, N. Sakamoto, N. Enomoto, H. Tanabe, M. Maekawa, M. Miyagishi, K. Taira, M. Watanabe, H. Mizusawa, Inhibition of intracellular hepatitis C Virus replication by synthetic and vector-derived small interfering RNAs, *EMBO Rep.* 4 (2003) 602–608.
- [5] M.Y. Seo, S. Abrignani, M. Houghton, J.H. Han, Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7, *J. Virol.* 77 (2003) 810–812.
- [6] M. Korf, D. Jarczak, C. Beger, M.P. Manns, M. Kruger, Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors, *J. Hepatol.* 43 (2005) 225–234.
- [7] A. Martin, F. Bodola, D.V. Sangar, K. Goettge, V. Popov, R. Rijnbrand, R.E. Lanford, S.M. Lemon, Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA, *Proc. Natl. Acad. Sci. USA* 100 (2003) 9962–9967.
- [8] K. Ishii, S. Iijima, N. Kimura, Y.-J. Lee, N. Ageyama, S. Yagi, K. Yamaguchi, N. Maki, K. Mori, S. Yoshizaki, S. Machida, T. Suzuki, N. Iwata, T. Sata, K. Terao, T. Miyamura, H. Akari, GBV-B as a pleiotropic virus: distribution of GBV-B in extrahepatic tissues in vivo, *Microb. Infect.* 9 (2007) 515–521.
- [9] K. Hirabayashi, J. Yano, T. Inoue, T. Yamaguchi, K. Tanigawara, G.E. Smyth, K. Ishiyama, T. Ohgi, K. Kimura, T. Irimura, Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity, *Cancer Res.* 59 (1999) 4325–4333.
- [10] J. Yano, K. Hirabayashi, S. Nakagawa, T. Yamaguchi, M. Nogawa, I. Kashimori, H. Naito, H. Kitagawa, K. Ishiyama, T. Ohgi, T. Irimura, Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer, *Clin. Cancer Res.* 10 (2004) 7721–7726.
- [11] M. Nogawa, T. Yuasa, S. Kimura, M. Tanaka, J. Kuroda, K. Sato, A. Yokota, M. Koizumi, T. Maekawa, Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer, *J. Clin. Invest.* 115 (2005) 978–985.
- [12] F. Liu, Y.K. Song, D. Liu, Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA, *Gene Ther.* 6 (1999) 1258–1266.
- [13] A.A. Kolyhalov, K. Mihalik, S.M. Feinstone, C.M. Rice, Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo, *J. Virol.* 74 (2000) 2046–2051.
- [14] J.R. Jacob, K.C. Lin, B.C. Tennant, K.G. Masnfield, GB virus B infection of the common marmoset (*Callithrix jacchus*) and associated liver pathology, *J. Gen. Virol.* 85 (2004) 2525–2533.
- [15] R.E. Lanford, D. Chavez, L. Notvall, K.M. Brasky, Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia, *Virology* 311 (2003) 72–80.
- [16] B.L. Jacobs, J.O. Langland, When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA, *Virology* 219 (1996) 339–349.
- [17] M.T. Mcmanus, Small RNAs and immunity, *Immunity* 21 (2004) 747–756.
- [18] J.N. Leonard, D.V. Shaffer, Antiviral RNAi therapy: emerging approaches for hitting a moving target, *Gene Ther.* 13 (2006) 532–540.
- [19] V. Bitko, A. Musiyenko, O. Shulyayeva, S. Barik, Inhibition of respiratory viruses by nasally administered siRNA, *Nat. Med.* 11 (2005) 50–55.
- [20] W. Zhang, H. Yang, X. Kong, S. Mohapatra, H. San Juan-Vergara, G. Hellermann, S. Behera, R. Singam, R.F. Lockey, S.S. Mohapatra, Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene, *Nat. Med.* 11 (2005) 56–62.
- [21] B.J. Li, Q. Tang, D. Cheng, C. Qin, F.Y. Xie, Q. Wei, J. Xu, Y. Liu, B.J. Zheng, M.C. Woodle, N. Zhong, P.Y. Lu, Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque, *Nat. Med.* 11 (2005) 944–9451.
- [22] S.M. Tompkins, C.Y. Lo, T.M. Tumpey, S.L. Epstein, Protection against lethal influenza virus challenge by RNA interference in vivo, *Proc. Natl. Acad. Sci. USA* 101 (2004) 8682–8686.
- [23] D. Palliser, D. Chowdhury, Q.Y. Wang, S.J. Lee, R.T. Bronson, D.M. Knipe, J. Lieberman, An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection, *Nature* 439 (2006) 89–94.
- [24] J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R.K. Pandey, T. Racie, K.G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, H.P. Vornlocher, M. Manoharan, H.P. Vornlocher, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, *Nature* 432 (2004) 173–178.
- [25] E. Song, P. Zhu, S.K. Lee, D. Chowdhury, D.M. Dykxhoorn, Y. Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, J. Lieberman, Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors, *Nat. Biotechnol.* 23 (2005) 709–717.

- [26] D.V. Morrissey, J.A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, N. Vaish, S. Zinnen, C. Vargeese, K. Bowman, C.S. Shaffer, L.B. Jeffs, A. Judge, I. MacLachlan, B. Polisky, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs, *Nat. Biotechnol.* 23 (2005) 1002–1007.
- [27] A.D. Judge, V. Sood, J.R. Shaw, D. Fang, K. McClintock, I. MacLachlan, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, *Nat. Biotechnol.* 23 (2005) 457–462.
- [28] T.S. Zimmeemamm, A.C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M.N. Fedoruk, J. Harborth, J.A. Heyes, L.B. Jeffs, M. John, A.D. Judge, K. Lam, K. McClintock, L.V. Nechev, L.R. Palmer, T. Racie, I. Rohl, S. Seiffert, S. Shanmugam, V. Sood, J. Soutschek, I. Toudjarska, A.J. Wheat, E. Yaworski, W. Zedalis, V. Koteliensky, M. Manoharan, H.P. Vornloche, I. MacLachlan, RNAi-mediated gene silencing in non-human primates, *Nature* 441 (2006) 111–114.
- [29] M. Schlee, V. Hornung, G. Hartmann, siRNA and isRNA: two edges of one sword, *Mol. Ther.* 14 (2006) 463–470.
- [30] R.E. Lanford, D. Chavez, B. Guerra, J.Y.N. Lau, Z. Hong, K.M. Brasky, B. Beames, Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes, *J. Virol.* 75 (2001) 8074–8081.
- [31] K. Li, Z. Chen, N. Kato, M. Gale Jr., S.M. Lemon, Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes, *J. Biol. Chem.* 280 (2005) 16739–16747.

Original article

GBV-B as a pleiotropic virus: distribution of GBV-B in extrahepatic tissues *in vivo*

Koji Ishii^a, Sayuki Iijima^b, Nobuyuki Kimura^b, Young-Jung Lee^b, Naohide Ageyama^b, Shintaro Yagi^{d,1}, Kenjiro Yamaguchi^d, Noboru Maki^d, Ken-ichi Mori^d, Sayaka Yoshizaki^a, Sanae Machida^{a,c}, Tetsuro Suzuki^a, Naoko Iwata^c, Tetsutaro Sata^c, Keiji Terao^b, Tatsuo Miyamura^a, Hirofumi Akari^{b,*}

^a Department of Virology II, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

^b Laboratory of Disease Control, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1-1 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan

^c Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

^d Advanced Life Science Institute, Wako, Saitama 351-0112, Japan

^e Department of Microbiology, Saitama Medical School, Moroyama-Cho, Iruma-Gun, Saitama 350-0495, Japan

Received 25 August 2006; accepted 16 January 2007

Available online 27 January 2007

Abstract

GB virus B (GBV-B) infection of New World monkeys is considered to be a useful surrogate model for hepatitis C virus (HCV) infection. GBV-B replicates in the liver and induces acute resolving hepatitis but little is known whether the other organs could be permissive for the virus. We investigated the viral tropism of GBV-B in tamarins in the acute stage of viral infection and found that the viral genomic RNA could be detected in a variety of tissues. Notably, a GBV-B-infected tamarin with marked acute viremia scarcely showed a sign of hepatitis, due to preferential infection in lymphoid tissues such as lymph nodes and spleen. These results indicate that GBV-B as well as HCV is a pleiotropic virus *in vivo*. © 2007 Elsevier Masson SAS. All rights reserved.

Keywords: GB virus B; Hepatitis C virus; Tamarin; Surrogate model

1. Introduction

Over 100 million people worldwide are carriers of hepatitis C virus (HCV) and the viral infection is a significant cause of human morbidity and mortality; chronic HCV infection in many cases will lead to liver cirrhosis and hepatocellular carcinoma. Furthermore, HCV infection manifests a variety of extrahepatic, at least in part due to the extrahepatic tropisms of HCV, particularly lymphotropic diseases (for review see [1]).

Other than humans, only chimpanzees that are endangered as species can be productively infected by HCV. Together with ethical issues regarding animal experiments, it has become increasingly difficult to access chimpanzees for experimental studies. Tamarins (*Saguinus* species), one of the new world monkeys, develop acute, self-limited hepatitis upon infection with the GB virus B (GBV-B), which is most closely related to HCV [2–4]. Although the acute nature of GBV-B infection in tamarins has been distinguished this hepatitis from HCV infection in humans, recent studies demonstrated that tamarins could be persistently infected by GBV-B and developed chronic hepatitis [5,6]. Therefore, the GBV-B infection of tamarins is proposed as a good surrogate model for hepatitis C. While GBV-B appeared to infect liver, comprehensive documentation of the *in vivo* tropism of GBV-B has not been

* Corresponding author. Tel.: +81 29 837 2121; fax: +81 29 837 0218.

E-mail address: akari@nibio.go.jp (H. Akari).

¹ Present address: Laboratory of Cellular Biochemistry, Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

reported yet. A previous report that GBV-B RNA was observed in peripheral blood mononuclear cells (PBMCs) from a GBV-B-infected marmoset [7] suggests that GBV-B may be lymphotropic as well as HCV. Considering the close similarity between HCV and GBV-B, we examined the viral distribution and tropism in tamarins in the acute phase of the viral infection.

2. Materials and methods

2.1. Animals

Adult white-lipped and Red-handed tamarins (*Saguinus labiatus* and *Saguinus midas*, respectively) were housed in individual cages at the Tsukuba Primate Research Center. All animal studies were conducted in accordance with the protocols of experimental procedures that were approved by the Animal Welfare and Animal Care Committees of the National Institute of Biomedical Innovation and National Institute of Infectious Diseases. The details of tamarins used in this study were summarized in Table 1.

2.2. GBV-B infection in tamarins

GBV-B RNA was transcribed *in vitro* with T7 RNA polymerase (Promega, Madison, WI) from 10 µg of *Xho*I-digested pGBB [2] that harbors infectious cDNA for GBV-B (kind gift of Dr. J. Bukh, National Institutes of Health, USA). The integrity of the RNA was checked by electrophoresis through an agarose gel stained with ethidium bromide. Each transcription mixture (400 µg of GBV-B RNA) was diluted with 400 µl of ice-cold water and then immediately frozen on dry ice and stored at -80°C . Transcription mixtures were injected into each tamarin intrahepatically. For transmission of GBV-B,

animals were infected intrahepatically with 100 µl of GBV-B infectious plasma containing 8×10^8 genome equivalents (GE) of the viral RNA. Blood samples were periodically collected from the monkeys from femoral vein under anesthetization and were tested for plasma ALT level.

2.3. Quantification of GBV-B genomic RNA

GBV-B-infected tamarins were euthanized and perfused with saline thoroughly before the collection of specimens including plasma, PBMCs and a variety of tissues (esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, liver, pancreas, submandibular gland, trachea, lung, bone marrow, thymus, spleen, submandibular lymph nodes, axillary lymph nodes, intestinal lymph nodes, mesenteric lymph nodes, inguinal lymph nodes, tonsil, heart, kidney, adrenal gland, bladder, brain, spinal cord, testis, uterus and ovary). GBV-B RNA from these specimens was quantified by a real-time, 5' exonuclease PCR (TaqMan) assay using a primer-probe combination that recognized a portion of the GBV-B capsid gene. The primers 558F [5'AACGAGCAAAGCGCAAAGTC] and 626R [5'CATCATGGATACCAGCAATTTTGT] and probe 579P [5'6FAM-AGCGCGATGCTCGGCCTCGTATAMRA] [8] were obtained from PE Biosystems. The primers were used at 15 pmol/50 µl reaction, and the probe was used at 10 pmol/50 µl reaction. Synthesized GBV-B RNA was used as a reference standard of GBV-positive plasma. PBMCs were isolated from whole blood by density-gradient centrifugation. Approximately 10 mg of tissues were removed under sterile conditions and immediately homogenized in 1 ml of TRIzol (Invitrogen, Carlsbad, CA) to extract RNA. We set our lowest detection cutoff at 10^2 GE per ml. All the specimens were evaluated in duplicates and the averages were shown.

Table 1
Summary of the results of GBV-B RNA levels in the tissues of the virus-infected tamarins

		Tm3	Tm4	Tm5	Tm6
Animals		<i>S. labiatus</i>	<i>S. midas</i>	<i>S. labiatus</i>	<i>S. midas</i>
Sex		Female	Female	Male	Female
GBV-B inoculum		Plasma	Plasma	RNA	RNA
Weeks at necropsy		4	4	3	ND ^a
ALT		321	522	38	554
Viral loads in:					
Blood	Plasma	3.8×10^8	5.9×10^8	1.3×10^{10}	2.8×10^9
	PBMC	270	1630	35650	ND
Spleen		(-) ^b	540	5980	ND
Lymph nodes	Inguinal	(-)	(-)	3090	ND
	Intestinal	(-)	(-)	640	ND
Liver		70080	33480	16080	ND
Kidney		(-)	(-)	380	ND
Testis				600	ND
Ovary		1290	150		ND
Bone marrow		120	(-)	750	ND

Viral loads in each tissues were presented as GE/mg except for plasma (GE/ml) and PBMC (GE/ 10^6 cells). Data for Tm6 were obtained at week 4.

^a ND: not done.

^b (-): undetectable.

2.4. Detection of anti-GBV-B core and NS3 antibodies by ELISA

The TrpE-core (aa 1 to 132) fusion protein and TrpE-NS3 (aa 1135 to 1378) fusion protein, representing a portion of NS3 identified as being immunogenic in infected animals [9], was expressed in *Escherichia coli* [10] to serve as an antigen to generate polyclonal rabbit antisera. Tamarin sera were tested for the presence of antibodies to GBV-B core and NS3 by ELISA as described previously [8].

2.5. Cloning of entire GBV-B genome from plasma, liver and PBMCs of infected tamarins

GBV-B RNA was isolated from plasma, liver and PBMCs as described above. GBV-B cDNA was synthesized using SuperScript reverse transcriptase II (Invitrogen) with GB-5145R primer (5'-GCG AGT GCG GCT GTC CCA GAA GTA TTG ACT-3') or GB-9051R primer (5'-AAT TTG GGG GTT CAG CTG ATG GCT AAT CCA-3'). After RNase H (Invitrogen) treatment at 42 °C, a cDNA mixture was subjected to PCR with LA-taq DNA polymerase (TaKaRa), GB-5145R primer and GB-35S primer (5'-ACC ACA AAC ACT CCA GTT TGT TAC ACT CCG CTA GG-3') or GB-9051R primer and GB-3999S primer (5'-CGT ACG GCG TGA ATC CAA ATT GCT ATT TTA-3') for 30 cycles of denaturation at 94 °C for 20 s and extension at 68 °C for 5 min. PCR products were purified from the gel using a QIA-quick gel kit (Qiagen), and then cloned into pGEM-T Easy vector (Promega). Four clones of each fragment were determined using a CEQ-2000XL analysis system with a DTCS quick start kit and GBV-B specific primers according to the manufacturer's instructions. Sequence data were analyzed on Macintosh computers with the Sequencer (Gene Code Corp.) and MacVector (Accelrys) software packages.

2.6. Synthesis of positive and negative standard RNAs for RT-PCR controls

Recombinant positive and negative strand RNAs were generated from pGBB containing 3' sequences of GBV-B. Positions 8569–9359 were amplified and inserted into pGEM-T easy vector. Clones were selected for sense and antisense orientation of the insert corresponding to positive and negative strands, respectively. Ten micrograms of the selected plasmids were linearized using *Pst*I and positive- and negative-strand RNAs were synthesized by transcription from the upstream T7 RNA polymerase promoter by Ambion MEGAscript T7 kit (Ambion, Austin, TX).

2.7. Detection of strand-specific viral RNA by tagging PCR system

One microgram of total RNA obtained from tissues or cells was subjected to RT-PCR. cDNAs were synthesized using Superscript III first strand synthesis system (Invitrogen). In order to overcome the detection of falsely primed cDNA products and make the PCR system strand-specific, additional

nucleotides (TCATGGTGGCGAATAA) were added to the 5' end of the reverse transcription primer (5'-TCATGGTGGCGAATAATTGGATTAGCCATCAGCTGAACC-3'), forming a "tag" (underlined) [11,12]. This "tag" sequence was neither complementary nor homologous to any part of the GBV-B genome. PCR amplification of a tagged cDNA was performed using only the tag portion of the cDNA primer (5'-TCATGGTGGCGAATAA-3') as one of the primers and a GBV-B specific oligonucleotide for the opposing primer (5'-CTTGGTACTACGCTCTGCACA-3', positions 9339–9359). For the first round of PCR using 2 µl of cDNA in a final volume of 25 µl, the reactions were performed using a TaKaRa PCR kit (TaKaRa) with following conditions; a 20 s and 94 °C denaturation step followed by 20 s and 55 °C annealing and 2 min and 72 °C extension steps. After 30 cycles of first round amplification, 2 µl of reaction samples were subjected to 30 cycles of nested PCR using 5'-TTTTAGGGCAGCGGCAACAG-3' (positions 9105–9124) and 5'-CACACAGCCAGGACTCCTCA-3' (positions 9260–9279) as primers.

2.8. Histopathology

Five tamarin livers were used in this study. Of these, three livers were from GBV-B-infected tamarins (Table 1), and two were from uninfected tamarins. Liver samples obtained by necropsy were fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4 µm thick-sections. Deparaffinized sections were stained with hematoxylin and eosin (H&E) for histopathological analyses. To investigate apoptotic cells in the livers, we also examined both DNA fragmentation and immunohistochemistry for an active form of caspase-3. To diminish autofluorescence mainly caused by lipofuscin, sections were pre-stained with 1% Sudan black B. DNA fragmentation was evaluated by a TUNEL assay with an ApopTag Direct *In Situ* Apoptosis Detection Kit (Chemicon International, Temecula, CA) according to the manufacturer's instructions. Briefly, the specimens were digested with a solution of proteinase K (20 µg/ml) in PBS for 5 min and then incubated with terminal deoxynucleotidyl transferase (TdT) and fluorescein-labeled nucleotides (ApopTag Direct) in a humid atmosphere at 37 °C for 1 h. Specimens were viewed with a BX-FLA fluorescence microscope (Olympus, Tokyo, Japan). To control for nonspecific incorporation of nucleotides and nonspecific binding of TdT, cells were treated with proteinase K as usual, but staining was performed in the absence of active TdT. This served as a negative control. In parallel, immunohistochemistry for an active form of caspase-3 was examined by using an FITC-conjugated monoclonal antibody against the active caspase-3 (C92-605; BD Pharmingen, San Jose, CA) in order to confirm the degree of apoptotic cells detected by TUNEL staining. Sections were deparaffinized followed by autoclaving for 5 min at 121 °C, and then incubated free floating in the primary antibody solution overnight at 4 °C. Following brief washes, sections were then incubated with DAPI (1:800; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature. These sections were examined with a Digital Eclipse C1 confocal microscope (Nikon, Japan).

3. Results

3.1. GBV-B infection in tamarins

Firstly, two tamarins were intrahepatically inoculated with RNA transcripts from GBV-B infectious molecular clone pGBB (Fig. 1). Both monkeys showed viremia at 2 weeks post inoculation; peak viral titers in plasma reached up to 10^9 GE/ml and both monkeys developed hepatitis with dramatically elevated plasma ALT levels. The viremia was maintained up to 8 weeks, followed by rapid decline in parallel with the resolution of the ALT abnormalities. Within 6–8 weeks of the inoculation, the development of antibodies reactive with the viral core and NS3 proteins was observed (Fig. 1). Multiple plasma samples collected at later time points contained no detectable viral RNA and showed no ALT abnormalities; however, antibodies against GBV-B core and NS3 proteins were maintained at relatively high levels at least until 28 weeks after inoculation (Fig. 1). These results confirmed that inoculation of GBV-B viral RNA caused acute hepatitis in parallel with typical viremia in tamarins.

Next, in order to examine the tissue tropism of GBV-B *in vivo*, four tamarins were inoculated intrahepatically with week 2 plasma of tamarin Tm1 containing 8×10^8 GE of GBV-B (Tm3 and Tm4) or synthetic GBV-B RNA as described above (Tm5 and Tm6). These tamarins developed a typical acute infection that were marked by high levels of viremia, indicating that inoculation of either viral RNA or plasma of the infected tamarin resulted in comparable outcome (Fig. 2). It is noteworthy that in Tm5 the plasma ALT level was scarcely elevated in contrast with other three tamarins during the acute period of GBV-B infection, although this tamarin developed highest viremia (1.3×10^{10} GE/ml).

3.2. Histopathological analyses of GBV-B infection

Histopathological analyses in Tm3 and Tm4 livers showed inflammatory responses including inflammatory cell invasions around central and/or portal veins and hemorrhages, hepatocytic degenerations, and disruptions of sinusoids (Fig. 3A,B,E,F). Although there were only minimal pathological changes, hepatocytic degenerations and dilation of sinusoids were also found in the Tm5 liver (Fig. 3C and G) in contrast to uninfected tamarins (Fig. 3D and H, data not shown). To further evaluate the levels of apoptotic hepatocytes in these monkeys, we employed two different methods, detecting fragmented DNA (TUNEL assay) and an active form of caspase-3 as previously described [13]. It was found that substantial numbers of fragmented DNA-positive cells were observed in the Tm3 and Tm4 livers while much less in the Tm5 liver (Fig. 3I–K). Consistent results were obtained when the active form of caspase-3 was stained (Fig. 3M–O). On the other hand, we found neither DNA fragmentation nor caspase-3 activation in uninfected tamarin livers (Fig. 3L and P, data not shown). The minimal levels of pathological changes in the Tm5 liver were well correlated with a lower level of plasma ALT in Tm5 (Fig. 2, Table 1).

3.3. Tissue distribution of GBV-B

The results described above suggested the possibility that the substantial levels of viral replication occurred in other tissues rather than in the liver of Tm5. To ascertain the possibility, we euthanized three tamarins (Tm3, Tm4 and Tm5) and the viral levels in a variety of tissues were compared. Table 1 summarizes the data obtained in this experiment. It is reasonable to consider that GBV-B replicated in the liver accounts for majority of the viral load *in vivo*. However,




Fig. 1. Course of GBV-B infection in tamarins Tm1 and Tm2. Synthesized infectious RNA transcript of GBV-B from a pGBB molecular clone was inoculated into each tamarin intrahepatically. Plasma samples were collected from each tamarin at 2-week intervals post inoculation. The viral RNA copies, ALT levels, and titers of anti-viral antibodies (anti-core and anti-NS3) in the plasma samples until 28 weeks after inoculation were shown.

substantial levels of GBV-B RNA were detected not only in the liver but also in a variety of extrahepatic tissues such as hemolymphoid and genital tissues, suggesting that GBV-B may infect and replicate in these organs. Notably, the viral RNA levels of Tm5 were much greater in the lymphoid tissues but lower in the liver as compared with those of other two tamarins, indicating that the highest plasma viral load in Tm5 derived from extrahepatic tissues, mainly hemolymphoid tissues. We could not detect GBV-B RNA from other tissues tested (data not shown). From these results, we concluded that the preferential distribution of GBV-B in the extrahepatic tissues rather than in the liver of Tm5 may attribute to the highest plasma viral load in spite of the mild disorder and the lower viral load in the liver.

In addition, the unique viral distribution implied that the GBV-B disseminated in Tm5 might acquire novel tissue tropism as a result of genomic mutation. To ascertain the possibility, we amplified the entire viral genomes by RT-PCR from the liver, PBMCs and plasma collected from Tm5 at euthanasia and compared with the original nucleotide sequence. The sequences determined were completely identical to the original sequence of GBV-B (data not shown), indicating that the sequence heterogeneity of GBV-B was not responsible for the different tropism observed in Tm5 and thus GBV-B intrinsically exhibits pleiotropism in a host-dependent manner.

3.4. Detection of strand-specific viral RNA in the tamarin tissues

To confirm that the virus was actually replicated in the tissues other than the liver, we sought to differentially determine negative-strand viral RNA which is shown to be a viral replication intermediate in case of HCV. We thus newly developed an assay system for detecting replication intermediate of GBV-B.

To determine the sensitivity of this method, synthetic positive- and negative-strand GBV-B transcripts (ranging from 10^8 to 10^0 copies of GBV-B) in 100-fold serial dilutions were subjected to RT-PCR. As shown in Fig. 4A, at least 100 copies of GBV-B negative-strand RNA could be detected by this method. When the primer for cDNA synthesis was omitted, no PCR products were obtained (Fig. 4A, negative control), indicating that the PCR signals were derived specifically from the GBV-B negative-strand RNA. In the presence of 10^8 copies of positive-strand HCV RNA, false positive PCR signals appeared (Fig. 4A). We then analyzed the samples from liver, spleen, pancreas, stomach and PBMCs from Tm5 using the GBV-B strand-specific PCR assay and found that the negative-strand viral RNAs were detected in the liver, spleen and PBMC samples (Fig. 4B). No negative-strand or replicating forms of the virus were detected from RNA extracted from pancreas, stomach and HeLa cells.




Fig. 2. Acute course of GBV-B infection in tamarins (Tm3 and Tm4) by *in vivo* passage of plasma (7.9×10^8 GE/head) obtained from the GBV-B RNA-inoculated Tm1 in comparison with GBV-B RNA transcript-inoculated tamarins (Tm5 and Tm6). The viral RNA copies and ALT levels in the plasma samples collected from each tamarin were indicated.




Fig. 3. Photomicrographs of liver sections from Tm3 (A, E, I, M), Tm4 (B, F, J, N), Tm5 (C, G, K, O), and an uninfected tamarin (D, H, L, P). A–H show sections with H&E staining, while I–L and M–P indicate sections with a TUNEL assay and immunohistochemistry for an active form of caspase-3, respectively. Sections immunostained for an active form of caspase-3 (green fluorescent) were counterstained with DAPI (blue fluorescent). Scale bars: 100 μ m.

4. Discussion

GBV-B is most closely related to HCV and induces acute resolving hepatitis in tamarins. It is therefore reasonable that GBV-B has been considered to be a hepatotropic virus; in this study, however, we show for the first time that GBV-B is a pleiotropic virus and can disseminate to not only liver but also a variety of extrahepatic tissues such as hematology and genital tissues. Of note, there is ample evidence that persistent HCV infection manifests a variety of extrahepatic diseases, at least in part due to the extrahepatic tropisms of HCV (for review see [1]). This also suggests that extrahepatic tissues may serve as alternative reservoirs for HCV, while further analyses should still be required to understand the viral dynamics *in vivo*. Considering the similar pleiotropism of HCV and GBV-B, our results support and extend the usefulness of New World primates infected with GBV-B as a surrogate model for the study of pathogenesis and tropism of HCV infection.

Tamarins infected with GBV-B generally develop semi-acute viremia, of which peak levels regularly ranged from 10^7 to 10^9 GE/ml on the basis of previous reports [2,5,6,

14,15]. From this point of view, the peak viremia (1.3×10^{10} GE/ml) in Tm5 euthanized at the acute phase of the viral infection appeared to be much greater than other cases. It seems likely that in Tm5 the lymphoid tissues but not liver were responsible for the highly efficient viral production, because (i)




Fig. 4. (A) Titration of synthetic GBV-B RNA transcripts. Synthetic RNA transcripts corresponding to the positive- and negative-strands of part of the GBV-B were serially diluted and each transcript was subjected to amplification using strand-specific RT-PCR to determine the specificity and sensitivity of the assays. (B) Detection of negative-strand GBV-B RNA from various tissues. One microgram of total RNA obtained from tissues or cells was subjected to RT-PCR.